Everolimus-containing therapy vs conventional therapy in the treatment of refractory breast cancer patients with PI3K/AKT/mTOR mutations: A retrospective study.
Zhanhong ChenYabing ZhengWenming CaoYuzi ZhangZhengyi ZhaoGuoqiang WangJing ZhaoShangli CaiXiying ShaoJian HuangWeiwu YeYuan HuangWei LiXiang HuangHao WuXiaojia WangYongmei YinPublished in: Cancer medicine (2019)
Our findings suggested that everolimus might not be effective for cancer patients harboring mutations in PI3K/ATK/mTOR pathway and physicians should be cautious about its off-label use in clinical practice.